CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A Cancer-Specific Plectin (CSP)-Targeting Functional Antibody in Solid Tumors That Are Likely to Express CSP

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05074472
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:20.935130+00:00
Published At: 2024-01-29T00:00:00+00:00
Record Updated At: 2024-01-29
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Solid Tumor, Adult", "Pancreatic Ductal; Adenocarcinoma", "Ovarian Serous Adenocarcinoma", "Biliary Cancer Metastatic", "Ovarian Serous Cystadenocarcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-01-29"
protocolSection.identificationModule.nctId: "NCT05074472"
protocolSection.identificationModule.officialTitle: "A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A Cancer-Specific Plectin (CSP)-Targeting Functional Antibody in Solid Tumors That Are Likely to Express CSP"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.